New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
10:23 EDTSWHC, RMTI, MTOR, APOL, NWBO, SBGI, UNXL, ACHN, VRTX, OHRPOptions with decreasing implied volatility
Options with decreasing implied volatility: OHRP VRTX ACHN UNXL SBGI NWBO APOL MTOR RMTI SWHC
News For OHRP;VRTX;ACHN;UNXL;SBGI;NWBO;APOL;MTOR;RMTI;SWHC From The Last 14 Days
Check below for free stories on OHRP;VRTX;ACHN;UNXL;SBGI;NWBO;APOL;MTOR;RMTI;SWHC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
07:25 EDTOHRPOhr Pharmaceutical management to meet with Brean Capital
Subscribe for More Information
July 17, 2014
11:12 EDTNWBOOptions with decreasing implied volatility
Subscribe for More Information
10:00 EDTMTOROn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:32 EDTSBGISinclair Broadcast launches American Sports Network
Subscribe for More Information
July 16, 2014
17:04 EDTMTORMeritor initiated with an Overweight at Piper Jaffray
Subscribe for More Information
08:20 EDTNWBONorthwest Biotherapeutics completes DCVax-Direct Phase 1 trial recruitment
Northwest Biotherapeutics announced that the Phase I portion of the company's Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment, and the company is now underway with preparations for the Phase II portion of this trial, as well as expansion of DCVax-Direct manufacturing. The Phase I/II trial is testing the safety and activity of DCVax-Direct in various types of cancer. The Phase I portion of the trial has involved testing of 3 different dose levels, and a diverse range of cancers. The patients enrolled in Phase I will continue to receive treatments in accordance with the protocol. With the closing of Phase I, the company is now preparing to initiate the Phase II portion of the trial. This second part of the Phase I/II study will target 24 or more patients in selected cancers. Additional trial sites are being brought on to facilitate and expedite enrollment. The company and its manufacturing partner, Cognate BioServices, are also expanding the manufacturing capacity for DCVax-Direct.
July 15, 2014
11:42 EDTSBGIDoJ requires Sinclair to make divestiture to proceed with Perpetual deal
Subscribe for More Information
09:59 EDTAPOLApollo Education discloses new Department of Education review
Subscribe for More Information
09:21 EDTAPOLOn The Fly: Pre-market Movers
Subscribe for More Information
09:04 EDTSBGISinclair Broadcast reaches retransmission consent with Buckeye Cable
Subscribe for More Information
07:17 EDTAPOLApollo Education Title IV review not cause for concern, says William Blair
William Blair says Apollo Education's announcement that the Department of Education will conduct a Title IV program review is not a major cause for concern. The firm notes that all U.S. colleges whose students access federal student loans are subject to periodic program reviews of their administration of Title IV funds. William Blair views Apollo's financial aid processing systems and procedures are among the best, if not the best, and keeps an Market Perform rating on the stock.
06:50 EDTAPOLApollo Education Title IV review likely non-event, says Piper Jaffray
After Apollo Education disclosed that the Department of Education will conduct a Title IV program review, Piper Jaffray says such actions are "normal course of business" and not unusual at for-profit institutions. Piper notes that Apollo's last Title IV program review was completed in 2012 with no adverse findings. The firm sees a "high probability" the review will be a non-event and it keeps a Neutral rating on the stock.
July 14, 2014
18:15 EDTAPOLOn The Fly: After Hours Movers
Subscribe for More Information
16:34 EDTAPOLApollo Education down nearly 8% after DoE review
Subscribe for More Information
16:30 EDTAPOLDoE to conduct review on Apollo's University of Phoenix financial aid program
Apollo Education disclosed in a regulatory filing that it has been informed by the U.S. Department of Education that the Department intends to conduct an ordinary course program review of University of Phoenix’s administration of federal student financial aid ,Title IV, programs in which the University participates. The review, which is scheduled to commence August 4, initially will cover federal financial aid years 2012-2013 and 2013-2014, as well as compliance with the Jeanne Clery Disclosure of Campus Security Policy and Campus Crime Statistics Act, the Drug-Free Schools and Communities Act and related regulations.
July 11, 2014
16:14 EDTOHRPVisium Asset reports 5.2% passive stake in Ohr Pharmaceutical
July 10, 2014
14:31 EDTNWBONorthwest Biotherapeutics rises 2.2% to $6.58
Subscribe for More Information
11:55 EDTSBGISigns show Sinclair Broadcast near closing Albritton deal, says Wells Fargo
Subscribe for More Information
08:02 EDTVRTXVertex announces retirement of Chief Scientific Officer Mueller
Subscribe for More Information
July 8, 2014
10:28 EDTVRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use